Wilson Sonsini tops Life Sciences Law Firm Index for 2nd straight year
The Life Sciences Law Firm Index identifies the most active and relevant firms for life science companies.
The Life Sciences Law Firm Index identifies the most active and relevant firms for life science companies.
Leaders of WilmerHale’s life sciences practice share trends they see regarding acquisitions and initial public offerings.
Still recovering from a market correction two years ago, and with a scarcity of attractive targets and ongoing macroeconomic uncertainty, the life sciences dealmaking space is in a state of flux.
After a relatively slow 2016 for life sciences deals...
Last year proved a slow one for dealmaking in the life sciences space. But that didn’t stop two of the major legal players in it from consummating one themselves: In November, Arnold & Porter and Kaye Scholer agreed to merge, bringing together two formidable healthcare practices.
Lake Whillans is providing financial relief to insurance companies that offered plans on the Affordable Care Act’s health insurance exchanges and are now impaired by the government’s delay in making promised so-called “risk corridor payments.”
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
When it comes to fighting disease, Michael Shuster takes things personally...
This independent editorial series on healthcare and the law is sponsored by Lake Whillans, a distressed venture capital and litigation finance firm that helps companies facing litigation or arbitration. As states began to jump onto the pharmaceutical regulation bandwagon around the turn of the century, Porzio Bromberg & Newman brought John Ohoro on to help clients sift […]
Not too long ago, it didn’t take much for someone with an idea for a new medical device to rake in the early-stage funding. Investors have been a bit more discerning over the past decade, to say the least, and by and large they remain so, according to K&L Gates’ Michael Hedge, who’s been around long enough to […]
These are tough times in the biotech and pharmaceutical industries: Funding is drying up, investors are fleeing the space, the IPO door is pretty firmly shut, valuations are dropping, activists are lurking and the headlines are anything but kind. But when the going gets tough, the tough consider strategic alternatives. Stuart Falber and Belinda Juran, […]
The life sciences — particularly in biotechnology and pharmaceuticals — are among the very few industries where companies insist on industry-specialized advisors. The complex life cycle of a life sciences product demands a broad range of legal and business expertise across many practice specialties, combined with deep scientific knowledge. The stakes are increasing particularly when […]
Throughout the year Lake Whillans, with the help of MedCity News, has explored two key issues for healthcare investors and entrepreneurs: trust and reliability. We’ve helped bring to light some harrowing war stories of partnerships gone bad. We’ve also asked healthcare leaders in the trenches about the best ways to operate in the modern healthcare […]
Everyone loves the backup quarterback because they’ve never played a down. But once those backups play, the sports analogy goes, and they are almost always worse than the starter. Are digital health VCs the backup quarterbacks of healthcare investing? Rightfully, there’s a lot of excitement about corporate venture’s increasing prominence in healthcare. But don’t get […]
Part II in our research examining which corporate venture capitalists you can trust and rely on.
If you run a startup, do these three rules resonate?